Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: UVA Irradiation Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers

NCT01115322
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene Foam without irradiation, Tazarotene Foam with UVA and UVB irradiation, Tazarotene Foam with UVA, UVB, and visible light, Vehicle Foam without irradiation, Vehicle Foam with UVA and UVB irradiation, Vehicle Foam with UVA and UVB and visible light irradiation, No Treatment without irradiation, No Treatment with UVA and UVB irradiation, No Treatment with UVA and UVB and visible light irradiation
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 8, 2026, 5:02 AM EDT
Not listed No phase listed Observational

UVA Brain and Aortic Aneurysm Study

NCT02869464
View directory record Official record
Conditions
Intracranial Aneurysm, Abdominal Aortic Aneurysm
Interventions
Imaging-Ultrasound, Imaging-MRA, DNA, RNA testing
Other · Genetic
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

Corneal Collagen Cross-Linking for Ectasia (CXL)

NCT00674661
View directory record Official record
Conditions
Ectasia
Interventions
riboflavin ophthalmic solution, UVA Irradiation
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
14 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Phototoxicity Test

NCT02750475
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreen Sport Lotion (BAY987516), Untreated Skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

To Test for Photo Allergy Reaction of Sunscreens

NCT02872220
View directory record Official record
Conditions
Photoallergy
Interventions
SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Pinellas Park, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Cutaneous Effects of Deep Ultraviolet A +/- High-Energy Visible Blue Light Exposure

NCT06654102
View directory record Official record
Conditions
Skin Pigmentation, Photobiology
Interventions
Deep UVA Irradiation, Deep UVA+HEV Blue Light Irradiation
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Union City, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking in Eyes With Refractory Corneal Infection

NCT02068430
View directory record Official record
Conditions
Corneal Ulcers
Interventions
Riboflavin 0.1%, UV-X™ Illumination System
Drug · Other
Lead sponsor
Stephen Trokel
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 8, 2026, 5:02 AM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Progressive Keratoconus or Ectasia Treatment Plan

NCT01384773
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Riboflavin Solution, UV-X Illumination System
Other · Device
Lead sponsor
Stephen Trokel
Other
Eligibility
16 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01643226
View directory record Official record
Conditions
Keratoconus
Interventions
riboflavin solution, placebo solution, KXL System
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
8
States / cities
San Diego, California • Indianapolis, Indiana • Overland Park, Kansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

NCT01119651
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Patch application in Challenge Phase)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 13, 2017 · Synced Sep 8, 2026, 5:02 AM EDT
Withdrawn Not applicable Interventional

Higher Irradiance in Keratoconus Ectasia

NCT01789333
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
UVA Light with irradiance exposure of 9 mW/cm2, Riboflavin 0.1% ophthalmic solution
Device · Drug
Lead sponsor
Stephen Trokel
Other
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Sep 8, 2026, 5:02 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety and Efficacy of Corneal Collagen Cross-linking Following LASIK for Treatment of Hyperopia and Hyperopic Astigmatism

NCT01893359
View directory record Official record
Conditions
Hyperopia, Hyperopic Astigmatism
Interventions
riboflavin ophthalmic solution, 0% dextran, UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA), UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off), Laser-assisted in situ keratomileusis
Drug · Device · Procedure
Lead sponsor
Glaukos Corporation
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
San Diego, California • Waltham, Massachusetts • Teaneck, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18794 - Human Photo Toxicity Test

NCT02751372
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY 987517, Untreated Skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 8, 2026, 5:02 AM EDT
Terminated Phase 1 Interventional Results available

Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)

NCT05457491
View directory record Official record
Conditions
Skin Aging
Interventions
Human platelet extract (cosmetic product), Vanicream Gentle Facial Cleanser, EltaMD UV Daily Broad-Spectrum SPF 40, EltaMD PM Therapy Facial Moisturizer, Vanicream Lite Lotion
Biological · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Sep 8, 2026, 5:02 AM EDT
Terminated Phase 3 Interventional

Safety and Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01972854
View directory record Official record
Conditions
Keratoconus
Interventions
riboflavin solution, placebo solution, KXL System
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
11
States / cities
Irvine, California • San Diego, California • Indianapolis, Indiana + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit

NCT02863809
View directory record Official record
Conditions
Keratolysis
Interventions
Riboflavin, Dextran, UVA Light Source
Drug · Device
Lead sponsor
Joseph B. Ciolino, MD
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
13
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Sep 8, 2026, 5:02 AM EDT
Terminated Phase 3 Interventional

Safety & Efficacy of Corneal Collagen Cross-Linking in Eyes With Keratoconus or Corneal Ectasia After Refractive Surgery

NCT01459679
View directory record Official record
Conditions
Keratoconus, Corneal Ectasia
Interventions
KXL System (15 mW/cm2), KXL System (30 mW/cm2), KXL System (45 mW/cm2), riboflavin ophthalmic solution
Device · Drug
Lead sponsor
American-European Congress of Ophthalmic Surgery
Network
Eligibility
12 Years and older
Enrollment
1,721 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
82
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 71 more
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

Corneal Collagen Cross-linking for Progressive Keratoconus

NCT00647699
View directory record Official record
Conditions
Progressive Keratoconus
Interventions
riboflavin ophthalmic solution, UVA Irradiation
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
14 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
10
States / cities
La Jolla, California • San Diego, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus as Secondary Therapy in Chronic Graft-Versus-Host Disease Not Responding To Prior Treatment

NCT00079183
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
sirolimus
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Not listed
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Human Phototoxicity Test

NCT02751541
View directory record Official record
Conditions
Sunscreening Agents
Interventions
Sunscreen Sport Spray (BAY987519), Untreated Skin
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Corneal Collagen Cross-Linking in Eyes With Keratoconus

NCT01344187
View directory record Official record
Conditions
Keratoconus
Interventions
riboflavin solution, placebo solution, KXL System
Drug · Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
12 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
10
States / cities
Irvine, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Ability of Sunscreen Products to Modulate the Effects of Deep UVA +/- HEV Blue Light Induced Pigmentation and Biomarkers of Cutaneous Oxidative Stress

NCT07695753
View directory record Official record
Conditions
Pigmentation, Oxidative Stress
Interventions
Sunscreen application #1, Sunscreen application #2
Other
Lead sponsor
Kenvue Brands LLC
Industry
Eligibility
18 Years to 60 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 8, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Test the Phototoxicity of Sunscreen Products

NCT02802930
View directory record Official record
Conditions
Sunscreen Agents
Interventions
SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Pinellas Park, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 8, 2026, 5:02 AM EDT
Not listed Phase 2Phase 3 Interventional

Collagen Cross-Linking for Keratoconus/Ectasia With and Without Intacs

NCT01081561
View directory record Official record
Conditions
Keratoconus, Ectasia
Interventions
Riboflavin
Drug
Lead sponsor
Yaron S. Rabinowitz M.D.
Other
Eligibility
21 Years to 65 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Sep 8, 2026, 5:02 AM EDT